Chi Sheng Chemical
Chi Sheng Pharma & Biotech Co., Ltd manufactures, processes, imports, exports, and sells western medicines, cosmetics, health food products, medical devices, and animal medicines in Taiwan and internationally. Its product portfolio includes antibiotics and chemotherapeutic agents; plasma substitutes and amino acid preparations; water nutrients and electrolyte preparations; vitamins; hepatotropic … Read more
Chi Sheng Chemical (4111) - Net Assets
Latest net assets as of June 2025: NT$1.29 Billion TWD
Based on the latest financial reports, Chi Sheng Chemical (4111) has net assets worth NT$1.29 Billion TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.84 Billion) and total liabilities (NT$550.20 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.29 Billion |
| % of Total Assets | 70.12% |
| Annual Growth Rate | 2.76% |
| 5-Year Change | 18.48% |
| 10-Year Change | N/A |
| Growth Volatility | 3.77 |
Chi Sheng Chemical - Net Assets Trend (2017–2024)
This chart illustrates how Chi Sheng Chemical's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Chi Sheng Chemical (2017–2024)
The table below shows the annual net assets of Chi Sheng Chemical from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.27 Billion | +4.55% |
| 2023-12-31 | NT$1.22 Billion | -0.25% |
| 2022-12-31 | NT$1.22 Billion | +11.03% |
| 2021-12-31 | NT$1.10 Billion | +2.32% |
| 2020-12-31 | NT$1.08 Billion | +0.37% |
| 2019-12-31 | NT$1.07 Billion | +2.55% |
| 2018-12-31 | NT$1.05 Billion | -0.80% |
| 2017-12-31 | NT$1.05 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Chi Sheng Chemical's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9.2% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$401.26 Million | 31.48% |
| Other Components | NT$873.29 Million | 68.52% |
| Total Equity | NT$1.27 Billion | 100.00% |
Chi Sheng Chemical Competitors by Market Cap
The table below lists competitors of Chi Sheng Chemical ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GIGANTE SALMON AS NK 1
F:96M
|
$41.88 Million |
|
LumenRadio AB
ST:LUMEN
|
$41.88 Million |
|
SUN KWANG CO.Ltd
KQ:003100
|
$41.90 Million |
|
Finger Inc.
KQ:163730
|
$41.93 Million |
|
Sajodongaone Co Ltd
KO:008040
|
$41.84 Million |
|
Lake Shore Bancorp Inc
NASDAQ:LSBK
|
$41.82 Million |
|
NEOWIZ HOLDINGS Corporation
KQ:042420
|
$41.81 Million |
|
Vivani Medical Inc.
NASDAQ:VANI
|
$41.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Chi Sheng Chemical's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,219,061,000 to 1,274,550,000, a change of 55,489,000 (4.6%).
- Net income of 110,633,000 contributed positively to equity growth.
- Dividend payments of 56,983,000 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$110.63 Million | +8.68% |
| Dividends Paid | NT$56.98 Million | -4.47% |
| Other Changes | NT$1.84 Million | +0.14% |
| Total Change | NT$- | 4.55% |
Book Value vs Market Value Analysis
This analysis compares Chi Sheng Chemical's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.38x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.58x to 1.38x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$18.49 | NT$29.30 | x |
| 2018-12-31 | NT$18.34 | NT$29.30 | x |
| 2019-12-31 | NT$18.73 | NT$29.30 | x |
| 2020-12-31 | NT$18.80 | NT$29.30 | x |
| 2021-12-31 | NT$19.22 | NT$29.30 | x |
| 2022-12-31 | NT$21.32 | NT$29.30 | x |
| 2023-12-31 | NT$20.37 | NT$29.30 | x |
| 2024-12-31 | NT$21.30 | NT$29.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Chi Sheng Chemical utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.68%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.49%
- • Asset Turnover: 0.67x
- • Equity Multiplier: 1.37x
- Recent ROE (8.68%) is above the historical average (7.29%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 7.76% | 7.83% | 0.70x | 1.41x | NT$-23.61 Million |
| 2018 | 4.04% | 4.37% | 0.64x | 1.44x | NT$-62.26 Million |
| 2019 | 6.76% | 7.08% | 0.67x | 1.42x | NT$-34.73 Million |
| 2020 | 5.50% | 6.04% | 0.66x | 1.38x | NT$-48.44 Million |
| 2021 | 7.34% | 7.90% | 0.62x | 1.51x | NT$-29.32 Million |
| 2022 | 12.60% | 13.47% | 0.63x | 1.47x | NT$31.79 Million |
| 2023 | 5.63% | 6.47% | 0.60x | 1.45x | NT$-53.23 Million |
| 2024 | 8.68% | 9.49% | 0.67x | 1.37x | NT$-16.82 Million |
Industry Comparison
This section compares Chi Sheng Chemical's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,859,925,222
- Average return on equity (ROE) among peers: 10.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Chi Sheng Chemical (4111) | NT$1.29 Billion | 7.76% | 0.43x | $41.85 Million |
| St.Shine Optical Co Ltd (1565) | $5.39 Billion | 29.48% | 0.60x | $147.19 Million |
| Nang Kuang Pharmaceutical Co Ltd (1752) | $2.19 Billion | 9.94% | 0.50x | $46.91 Million |
| Maxigen Biotech Inc (1783) | $1.14 Billion | 7.68% | 0.11x | $52.72 Million |
| SciVision Biotech Inc (1786) | $1.02 Billion | -2.16% | 0.07x | $107.78 Million |
| Bioteque (4107) | $1.88 Billion | 15.46% | 0.25x | $198.92 Million |
| Sunder Biomedical Tech. Co., Ltd. (4115) | $790.45 Million | 1.68% | 0.80x | $2.12K |
| BenQ Medical Technology (4116) | $1.10 Billion | 2.62% | 0.78x | $25.45 Million |
| Pacific Hospital Supply Co Ltd (4126) | $2.26 Billion | 10.49% | 0.61x | $128.74 Million |
| Unicon Optical Co., Ltd. (4150) | $963.23 Million | 21.57% | 0.59x | $22.68 Million |